ABCB1 Gene Variants and Antidepressant Treatment Outcomes: A Systematic Review and Meta-Analysis Including Results...

Area of Science:

• Pharmacogenetics
• Neuroscience
• Genetics

Background:

• The P-glycoprotein efflux pump, regulated by the ABCB1 gene, influences antidepressant concentrations in the brain.
• Major depressive disorder (MDD) treatment outcomes can be affected by genetic factors, including ABCB1 single-nucleotide polymorphisms (SNPs).

Approach:

• A systematic review and meta-analysis investigated six ABCB1 SNPs (rs1045642, rs2032582, rs1128503, rs2032583, rs2235015, rs2235040) and their association with antidepressant treatment outcomes in MDD.
• New data from the Canadian Biomarker and Integration Network for Depression (CAN-BIND-1) cohort were analyzed using regression models.
• 39 studies were included in the meta-analysis, examining ABCB1 SNPs in MDD patients treated with antidepressants.

Key Points:

• No significant association was found between the studied ABCB1 SNPs and antidepressant treatment outcomes in the CAN-BIND-1 cohort.
• The meta-analysis revealed a significant association between the ABCB1 SNP rs1128503 and antidepressant treatment response (OR=1.30, P=0.024, n=2,526).
• No significant associations were observed for any of the six SNPs with treatment remission or tolerability.

Conclusions:

• Current findings offer limited support for a link between common ABCB1 SNPs and antidepressant treatment outcomes in MDD.
• The results do not currently support the clinical implementation of ABCB1 genotyping to personalize antidepressant treatment strategies.
• Further research, particularly focusing on the rs1128503 SNP, is recommended to clarify its role in antidepressant response.